A new generation of targeted therapies, 10 times more efficient ADCs
Project from 2021 Allocated sum 500 000,00 €
Mablink Bioscience is developing its own platform to produce the next generation of more stable and potent ADCs (Antibody Drug Conjugate), using a patented hydrophilic cloak called PSARlink.
ADCs are a class of targeted cancer drugs. They use a monoclonal antibody to transport highly potent cytotoxic molecules directly and specifically into tumor cells to destroy them, while sparing healthy tissue.
To use a warlike analogy, to reach and destroy cancer cells, a “missile” (ADC) is injected into the body, consisting of a homing head (monoclonal antibody), a linker and a payload of toxic agents. The homing head clings to its target and then lets the toxic agents do their work in an ultra-localized way.
Unlike chemotherapy and radiotherapy, which do not differentiate between cells, ADCs allow cancer cells to be targeted with great precision, thus sparing healthy cells as much as possible.
An cloak of invisibility making this new generation of ADCs 10 times more efficient
Injected intravenously, ADCs circulate in the blood, passing through the various organs, in search of cancer cells. Every minute, 1.5 liters of blood passes through the liver to be filtered and cleaned of harmful elements. This is a delicate passage for toxic agents carried by ADCs that could be substracted, reducing the strike force against cancer cells and causing unwanted toxicity in the liver.
Mablink Bioscience’s project provides a solution with its cloak of invisibility (a patented polysarcosine called PSARlink) that covers the cytotoxic payload. It masks it from the filtering cells of the liver and thus allows the ADCs to continue their hunt against cancer cells.
Mablink estimates that the therapeutic index (efficiency/tolerance ratio) of this new generation of ADCs is 10 times better than the ADCs currently available.
Thanks to this PSARlink cloak and the associated technology platform, Mablink was able to complete the research development and preclinical proof of concept of these new generation ADCs in only 2 years.